What's Happening?
Johnson & Johnson's Rybrevant Faspro, a subcutaneous formulation of the EGFRxMET bispecific antibody amivantamab, has received accelerated approval from the FDA for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This marks the first time Rybrevant has been approved for an indication beyond lung cancer. The approval is specifically for adult patients whose disease has progressed on or after platinum-based chemotherapy and immunotherapy. The FDA's decision was based on data from the Phase 1b/2 OrigAMI-4 trial, which demonstrated a clinically meaningful 42% overall response rate (ORR), including 15% complete responses. Notably, 56% of these responses were maintained for at least six months. This approval represents the first new drug for this patient population in a decade.
Why It's Important?
The accelerated approval of Rybrevant Faspro is a significant advancement for patients with recurrent or metastatic HNSCC, a condition often associated with poor prognosis and limited treatment options after initial therapies fail. EGFR and MET overexpression, found in 80% to 90% of these tumors, are key drivers of cancer progression, making a targeted therapy like Rybrevant crucial. This new treatment offers renewed hope for patients who face severe symptoms affecting their ability to eat, speak, and breathe. The drug's efficacy in a patient population with high unmet needs underscores its potential to improve quality of life and extend survival, addressing a critical gap in current oncology practice.
What's Next?
The continued market availability of Rybrevant Faspro for HNSCC will depend on the results of the confirmatory Phase 3 OrigAMI-5 study. This study could also potentially expand the drug's use into the first-line setting for HNSCC. Johnson & Johnson is also actively investigating Rybrevant and Rybrevant Faspro-based therapies for other solid tumors driven by EGFR/MET mutations, including various advanced or metastatic colorectal cancer settings. The company's broader oncology franchise, including Rybrevant and oral EGFR inhibitor Lazcluze, has shown substantial growth, indicating a strong commercial trajectory for these targeted therapies.
Beyond the Headlines
This approval highlights the FDA's commitment to accelerating access to promising therapies for cancers with high unmet needs, even as confirmatory trials are ongoing. The shift to a subcutaneous formulation (Rybrevant Faspro) from the original intravenous version offers a more convenient and potentially less burdensome treatment experience for patients, which can significantly impact adherence and quality of life. The success of bispecific antibodies like amivantamab in targeting multiple pathways (EGFR and MET) represents a sophisticated approach in precision oncology, moving beyond single-target therapies. This could pave the way for more multi-targeted agents and flexible administration methods in cancer treatment, influencing future drug development strategies.
